• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

强化证据：在斯威士兰的医院出生监测中，无论产妇的艾滋病毒感染状况和多替拉韦暴露情况如何，神经管缺陷的发生率相似。

Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini.

作者信息

Gill Michelle M, Khumalo Philisiwe, Chouraya Caspian, Kunene Mthokozisi, Dlamini Futhi, Hoffman Heather J, Scheuerle Angela E, Nhlabatsi Bonisile, Mngometulu Wiseman, Dlamini-Madlopha Ntombikayise, Mthunzi Nompumelelo, Mofenson Lynne

机构信息

Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.

Elizabeth Glaser Pediatric AIDS Foundation, Mbabane, Eswatini.

出版信息

Open Forum Infect Dis. 2023 Aug 18;10(9):ofad441. doi: 10.1093/ofid/ofad441. eCollection 2023 Sep.

DOI:10.1093/ofid/ofad441
PMID:37720700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10502921/
Abstract

Birth defect surveillance in Eswatini in 2020-2021 identified 0.80% defects (197/24 599 live and stillborn infants). Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women, and 1320 women on efavirenz preconception, respectively, more definitively refuting the dolutegravir preconception NTD safety signal.

摘要

2020 - 2021年斯威士兰的出生缺陷监测发现缺陷率为0.80%（24599例活产和死产婴儿中有197例）。神经管缺陷（NTD）的患病率在孕前服用多替拉韦的4902名妇女中为0.08%，在17285名HIV阴性妇女中为0.08%，在孕前服用依非韦伦的1320名妇女中为0.15%，这更明确地驳斥了孕前服用多替拉韦的神经管缺陷安全信号。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d8a/10502921/0d04a505e65f/ofad441f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d8a/10502921/0d04a505e65f/ofad441f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d8a/10502921/0d04a505e65f/ofad441f1.jpg

相似文献

1
Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini.强化证据：在斯威士兰的医院出生监测中，无论产妇的艾滋病毒感染状况和多替拉韦暴露情况如何，神经管缺陷的发生率相似。
Open Forum Infect Dis. 2023 Aug 18;10(9):ofad441. doi: 10.1093/ofid/ofad441. eCollection 2023 Sep.
2
Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.多替拉韦与巴西抗逆转录病毒治疗女性的妊娠结局：一项回顾性全国队列研究。
Lancet HIV. 2021 Jan;8(1):e33-e41. doi: 10.1016/S2352-3018(20)30268-X.
3
Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection - 15 Jurisdictions, 2013-2017.HIV 感染女性妊娠的神经管缺陷-15 个司法管辖区，2013-2017 年。
MMWR Morb Mortal Wkly Rep. 2020 Jan 10;69(1):1-5. doi: 10.15585/mmwr.mm6901a1.
4
Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.产前暴露于度鲁特韦后出现的先天异常：一项加拿大监测研究。
BJOG. 2019 Oct;126(11):1338-1345. doi: 10.1111/1471-0528.15838. Epub 2019 Jul 3.
5
Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.多替拉韦及其他 HIV 整合酶抑制剂对叶酸转运途径影响的临床外推。
Drug Metab Dispos. 2019 Aug;47(8):890-898. doi: 10.1124/dmd.119.087635. Epub 2019 Jun 5.
6
Prevalence of neural tube defects, maternal HIV status, and antiretroviral therapy from a hospital-based birth defect surveillance in Kampala, Uganda.乌干达坎帕拉基于医院的出生缺陷监测中神经管缺陷、孕产妇 HIV 状况和抗逆转录病毒治疗的流行情况。
Birth Defects Res. 2022 Feb;114(3-4):95-104. doi: 10.1002/bdr2.1964. Epub 2021 Nov 11.
7
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.博茨瓦纳开展的一项观察性研究：在孕期开始使用多替拉韦或依非韦伦为基础的抗逆转录病毒治疗的安全性比较。
Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.
8
An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini.对斯威士兰使用多替拉韦治疗 HIV 相关高血糖症上市后报告的评估。
AIDS Res Ther. 2022 Nov 24;19(1):54. doi: 10.1186/s12981-022-00481-0.
9
[Neural tube defects and associated factors in liveborn and stillborn infants].[活产儿与死产儿中的神经管缺陷及相关因素]
J Pediatr (Rio J). 2003 Mar-Apr;79(2):129-34.
10
Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.分析妊娠期多替拉韦的药物警戒数据库。
Clin Infect Dis. 2020 Jun 10;70(12):2599-2606. doi: 10.1093/cid/ciz684.

引用本文的文献

1
Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.多替拉韦的上市后安全性问题：一项基于美国食品药品监督管理局不良事件报告系统数据库的药物警戒研究。
Front Pharmacol. 2025 Jul 30;16:1625601. doi: 10.3389/fphar.2025.1625601. eCollection 2025.
2
Dolutegravir Developmental Toxicity is Mitigated by Magnesium and Folate in Zebrafish Embryos.在斑马鱼胚胎中，镁和叶酸可减轻多替拉韦的发育毒性。
bioRxiv. 2025 Jun 25:2025.06.24.661395. doi: 10.1101/2025.06.24.661395.
3
HIV and Pregnancy: Navigating Complex Decision Making and Preventing Perinatal Transmission.

本文引用的文献

1
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.在南非，基于多替拉韦的一线抗逆转录病毒疗法治疗艾滋病毒感染者的实施情况和结果：一项回顾性队列研究。
Lancet HIV. 2023 May;10(5):e284-e294. doi: 10.1016/S2352-3018(23)00047-4. Epub 2023 Mar 28.
2
Neural tube defects: a review of global prevalence, causes, and primary prevention.神经管缺陷：全球患病率、病因及初级预防的综述。
Childs Nerv Syst. 2023 Jul;39(7):1703-1710. doi: 10.1007/s00381-023-05910-7. Epub 2023 Mar 8.
3
Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa.
艾滋病毒与妊娠：应对复杂决策并预防围产期传播。
Curr HIV/AIDS Rep. 2025 Jun 7;22(1):36. doi: 10.1007/s11904-025-00745-0.
4
Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.多替拉韦/拉米夫定在HIV-1感染孕妇管理中的作用：一项叙述性综述
Infect Dis Ther. 2025 Jan;14(1):59-80. doi: 10.1007/s40121-024-01085-z. Epub 2024 Dec 9.
5
Efficacy and Safety of DRG/3TC for Prophylaxis of HIV Perinatal Transmission: A Pilot Study (PREGNANCY).DRG/3TC预防HIV围产期传播的疗效与安全性：一项初步研究（妊娠）。
Open Forum Infect Dis. 2024 Nov 12;11(12):ofae672. doi: 10.1093/ofid/ofae672. eCollection 2024 Dec.
6
Safety of Antiretroviral Exposure During Pregnancy: Opportunities to Close Data Gaps.孕期抗逆转录病毒暴露的安全性：填补数据空白的机遇
Open Forum Infect Dis. 2024 Jul 23;11(8):ofae423. doi: 10.1093/ofid/ofae423. eCollection 2024 Aug.
7
Population-based prevalence of congenital defects in a routine sentinel site-based surveillance system in the Western Cape, South Africa.南非西开普省常规哨点监测系统中先天性缺陷的基于人群的患病率。
Birth Defects Res. 2024 Aug;116(8):e2388. doi: 10.1002/bdr2.2388.
8
"No One Needs to be Forced": Qualitative Insights on Competing Priorities between Antiretroviral Therapy and Reproductive Health Planning during the Dolutegravir Rollout.“无需强迫”：在多拉韦林推出期间，抗逆转录病毒治疗与生殖健康规划之间存在竞争优先事项的定性分析。
AIDS Behav. 2024 Nov;28(11):3719-3732. doi: 10.1007/s10461-024-04454-4. Epub 2024 Jul 31.
9
Pharmacovigilance in Pregnancy Studies, Exposures and Outcomes Ascertainment, and Findings from Low- and Middle-Income Countries: A Scoping Review.妊娠研究中的药物警戒、暴露和结局确定，以及来自中低收入国家的发现：范围综述。
Drug Saf. 2024 Oct;47(10):957-990. doi: 10.1007/s40264-024-01445-1. Epub 2024 Jun 21.
10
First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort.美国队列研究中，孕妇在妊娠早期接触新型抗逆转录病毒药物与先天畸形的关系。
AIDS. 2024 Sep 1;38(11):1686-1695. doi: 10.1097/QAD.0000000000003955. Epub 2024 Jun 11.
在撒哈拉以南非洲地区，让女性转而采用一线首选的替诺福韦酯-拉米夫定-依非韦伦（TLD）治疗方案的工作进展滞后。
Clin Infect Dis. 2022 Jul 5. doi: 10.1093/cid/ciac555.
4
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.博茨瓦纳的神经管缺陷和抗逆转录病毒治疗方案。
N Engl J Med. 2019 Aug 29;381(9):827-840. doi: 10.1056/NEJMoa1905230. Epub 2019 Jul 22.
5
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.受孕时使用多替拉韦治疗导致的神经管缺陷。
N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24.
6
Teratogenicity risk of antiretroviral therapy in pregnancy.孕期抗逆转录病毒疗法的致畸风险。
Curr HIV/AIDS Rep. 2007 Aug;4(3):135-40. doi: 10.1007/s11904-007-0020-y.